Effects and significance of formononetin on expression levels of HIF‑1α and VEGF in mouse cervical cancer tissue

Zhang,Yue; Chen,Chen; Zhang,Jun

doi:10.3892/ol.2019.10567

Effects and significance of formononetin on expression levels of HIF‑1α and VEGF in mouse cervical cancer tissue

Authors:
- Yue Zhang
- Chen Chen
- Jun Zhang
View Affiliations

Affiliations: Department of Gynaecology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu 214023, P.R. China
Published online on: July 5, 2019 https://doi.org/10.3892/ol.2019.10567
Pages: 2248-2253
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effects and significance of formononetin on the expression levels of hypoxia‑inducible factor‑1α (HIF‑1α) and vascular endothelial growth factor (VEGF) in mouse cervical cancer tissue were investigated. The animal models of Balb/c nude mice with cervical cancer were established by the inoculation of HeLa cells, and randomly divided into positive control (n=10), cisplatin (n=15) and formononetin group (n=15). Mice were all sacrificed on the 31st day after administration, and their tumors were excised and weighed to calculate tumor inhibition rate. At the same time, their cancer tissues were obtained. RT‑qPCR was used for detecting the mRNA expression levels of HIF‑1α and VEGF, and western blotting for detecting the protein expression levels. During the medication intervention, mice in the formononetin group had no obvious adverse reactions, and were in good condition, whereas mice in the cisplatin group had poor appetite, drooping spirits and decreased activity. Mice in the cisplatin and the formononetin groups had significantly lower tumor mass and volume than those in the positive control group (P<0.05). The tumor inhibition rate of mice was 56.24% in the cisplatin group, and 50.17% in the formononetin group. Cervical cancer mice in the formononetin and the cisplatin groups had significantly lower mRNA and protein expression levels of HIF‑1α and VEGF in tissues than those in the positive control group (P<0.05). Formononetin can inhibit the growth of cervical cancer and reduce the mRNA and protein expression levels of HIF‑1α and VEGF in mouse cervical cancer. Formononetin has an inhibitory effect on cervical cancer tumors similar to that of cisplatin, but the former has smaller side effects, providing data for the clinical use in cervical cancer.

View Figures

View References

1	Li X, Zheng R, Li X, Shan H, Wu Q, Wang Y and Chen W: Trends of incidence rate and age at diagnosis for cervical cancer in China, from 2000 to 2014. Chin J Cancer Res. 29:477–486. 2017. View Article : Google Scholar : PubMed/NCBI
2	Cao S, Liu W, Li F, Zhao W and Qin C: Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer. Int J Clin Exp Pathol. 7:6776–6783. 2014.PubMed/NCBI
3	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
4	Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, Barretos Cancer Hospital, Baylor College of Medicine, Beckman Research Institute of City of Hope, Buck Institute for Research on Aging, Canada's Michael Smith Genome Sciences Centre, Harvard Medical School, Helen F. Graham Cancer Center &Research Institute at Christiana Care Health Services, ; et al: Integrated genomic and molecular characterization of cervical cancer. Nature. 543:378–384. 2017. View Article : Google Scholar : PubMed/NCBI
5	WHO Guidelines Approved by the Guidelines Review Committee, . Comprehensive cervical cancer control: a guide to essential practice. 2nd. World Health Organization; Geneva: 2014
6	Du PL, Wu KS, Fang JY, Zeng Y, Xu ZX, Tang WR, Xu XL and Lin K: Cervical cancer mortality trends in China, 1991–2013, and predictions for the future. Asian Pac J Cancer Prev. 16:6391–6396. 2015. View Article : Google Scholar : PubMed/NCBI
7	Wang J, Li G, Wang Y, Tang S, Sun X, Feng X, Li Y, Bao G, Li P, Mao X, et al: Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis. Oncotarget. 6:44579–44592. 2015. View Article : Google Scholar : PubMed/NCBI
8	Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 211:781–790. 2014. View Article : Google Scholar : PubMed/NCBI
9	Wigerup C, Påhlman S and Bexell D: Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther. 164:152–169. 2016. View Article : Google Scholar : PubMed/NCBI
10	Jussila L and Alitalo K: Vascular growth factors and lymphangiogenesis. Physiol Rev. 82:673–700. 2002. View Article : Google Scholar : PubMed/NCBI
11	Rocha SF, Schiller M, Jing D, Li H, Butz S, Vestweber D, Biljes D, Drexler HC, Nieminen-Kelhä M, Vajkoczy P, et al: Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res. 115:581–590. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhao K, Song X, Huang Y, Yao J, Zhou M, Li Z, You Q, Guo Q and Lu N: Wogonin inhibits LPS-induced tumor angiogenesis via suppressing PI3K/Akt/NF-κB signaling. Eur J Pharmacol. 737:57–69. 2014. View Article : Google Scholar : PubMed/NCBI
13	Hosaka M, Watari H, Takeda M, Moriwaki M, Hara Y, Todo Y, Ebina Y and Sakuragi N: Treatment of cervical cancer with adjuvant chemotherapy versus adjuvant radiotherapy after radical hysterectomy and systematic lymphadenectomy. J Obstet Gynaecol Res. 34:552–556. 2008. View Article : Google Scholar : PubMed/NCBI
14	Siva S, Herschtal A, Thomas JM, Bernshaw DM, Gill S, Hicks RJ and Narayan K: Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer. 117:3981–3988. 2011. View Article : Google Scholar : PubMed/NCBI
15	Lee HJ, Kim YS, Shin SS, Nam JH, Kim YT, Han S and Choi EK: Long-term outcomes of concomitant chemoradiotherapy incorporating high-dose-rate brachytherapy to treat locally advanced cervical cancer. Tumori. 98:615–621. 2012. View Article : Google Scholar : PubMed/NCBI
16	Casagrande N, De Paoli M, Celegato M, Borghese C, Mongiat M, Colombatti A and Aldinucci D: Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer. Gynecol Oncol. 131:744–752. 2013. View Article : Google Scholar : PubMed/NCBI
17	Agyemang K, Han L, Liu E, Zhang Y, Wang T and Gao X: Recent advances in astragalus membranaceus anti-diabetic research: pharmacological effects of its phytochemical constituents. Evid Based Complement Alternat Med. 2013:6546432013. View Article : Google Scholar : PubMed/NCBI
18	Sun T, Wang J, Huang LH and Cao YX: Antihypertensive effect of formononetin through regulating the expressions of eNOS, 5-HT2A/1B receptors and α1-adrenoceptors in spontaneously rat arteries. Eur J Pharmacol. 699:241–249. 2013. View Article : Google Scholar : PubMed/NCBI
19	Ha H, Lee HY, Lee JH, Jung D, Choi J, Song KY, Jung HJ, Choi JS, Chang SI and Kim C: Formononetin prevents ovariectomy-induced bone loss in rats. Arch Pharm Res. 33:625–632. 2010. View Article : Google Scholar : PubMed/NCBI
20	Huh JE, Nam DW, Baek YH, Kang JW, Park DS, Choi DY and Lee JD: Formononetin accelerates wound repair by the regulation of early growth response factor-1 transcription factor through the phosphorylation of the ERK and p38 MAPK pathways. Int Immunopharmacol. 11:46–54. 2011. View Article : Google Scholar : PubMed/NCBI
21	Wu Y, Zhang X, Li Z, Yan H, Qin J and Li T: Formononetin inhibits human bladder cancer cell proliferation and invasiveness via regulation of miR-21 and PTEN. Food Funct. 8:1061–1066. 2017. View Article : Google Scholar : PubMed/NCBI
22	Zhou R, Xu L, Ye M, Liao M, Du H and Chen H: Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. Horm Metab Res. 46:753–760. 2014. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 [-Delta Delta C(T)] method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, et al: Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol. 56:1343–1350. 2012. View Article : Google Scholar : PubMed/NCBI
25	Waggoner SE: Cervical cancer. Lancet. 361:2217–2225. 2003. View Article : Google Scholar : PubMed/NCBI
26	Mahasiripanth T, Hokputsa S, Niruthisard S, Bhattarakosol P and Patumraj S: Effects of Acanthus ebracteatus Vahl on tumor angiogenesis and on tumor growth in nude mice implanted with cervical cancer. Cancer Manag Res. 4:269–279. 2012.PubMed/NCBI
27	Eckert AW, Lautner MH, Schütze A, Taubert H, Schubert J and Bilkenroth U: Coexpression of hypoxia-inducible factor-1α and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients. Histopathology. 58:1136–1147. 2011. View Article : Google Scholar : PubMed/NCBI
28	Shi D, Guo W, Chen W, Fu L, Wang J, Tian Y, Xiao X, Kang T, Huang W and Deng W: Nicotine promotes proliferation of human nasopharyngeal carcinoma cells by regulating α7AChR, ERK, HIF-1α and VEGF/PEDF signaling. PLoS One. 7:e438982012. View Article : Google Scholar : PubMed/NCBI
29	Chen Y, Liu BL, Shang B, Chen AS, Liu SQ, Sun W, Yin HZ, Yin JQ and Su Q: Nutrition support in surgical patients with colorectal cancer. World J Gastroenterol. 17:1779–1786. 2011. View Article : Google Scholar : PubMed/NCBI
30	Kayl AE and Meyers CA: Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr Opin Obstet Gynecol. 18:24–28. 2006. View Article : Google Scholar : PubMed/NCBI
31	Hu W and Xiao Z: Formononetin induces apoptosis of human osteosarcoma cell line U2OS by regulating the expression of Bcl-2, Bax and MiR-375 in vitro and in vivo. Cell Physiol Biochem. 37:933–939. 2015. View Article : Google Scholar : PubMed/NCBI
32	Ren J, Xu HJ, Cheng H, Xin WQ, Chen X and Hu K: Synthesis and antitumor activity of formononetin nitrogen mustard derivatives. Eur J Med Chem. 54:175–187. 2012. View Article : Google Scholar : PubMed/NCBI
33	Chen J and Sun L: Formononetin-induced apoptosis by activation of Ras/p38 mitogen-activated protein kinase in estrogen receptor-positive human breast cancer cells. Horm Metab Res. 44:943–948. 2012. View Article : Google Scholar : PubMed/NCBI
34	Kim NS, Kang YJ, Jo JO, Kim HY, Oh YR, Kim YO, Jung MH, Ock MS and Cha HJ: Elevated expression of thymosin β4, vascular endothelial growth factor (VEGF), and hypoxia inducible factor (HIF)-1α in early-stage cervical cancers. Pathol Oncol Res. 17:493–502. 2011. View Article : Google Scholar : PubMed/NCBI
35	Bachtiary B, Schindl M, Pötter R, Dreier B, Knocke TH, Hainfellner JA, Horvat R and Birner P: Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res. 9:2234–2240. 2003.PubMed/NCBI
36	Birner P, Schindl M, Obermair A, Plank C, Breitenecker G and Oberhuber G: Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60:4693–4696. 2000.PubMed/NCBI
37	Chen WT, Huang CJ, Wu MT, Yang SF, Su YC and Chai CY: Hypoxia-inducible factor-1alpha is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor. Jpn J Clin Oncol. 35:207–213. 2005. View Article : Google Scholar : PubMed/NCBI
38	Jin YM, Xu TM, Zhao YH, Wang YC and Cui MH: In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa. Tumour Biol. 35:2279–2284. 2014. View Article : Google Scholar : PubMed/NCBI